Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADepT-PD: Escitalopram vs Nortriptyline for Depression in Parkinson's Disease
NCT03652870Phase 3Completed
- Sponsor
- University College London
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Escitalopram oxalate oral solution and nortriptyline in major depressive disorder (MDD) (3 arms), sponsored by University College London. Primary endpoint: Depressive symptoms at 8 weeks. Started Mar 2021; status: completed.
02
Drugs
Escitalopram oxalate oral solutionnortriptyline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03652870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03652870.